MedTrace Logo

Greatest International Antiinfective Trial With Avelox

NCT00932802 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50000

Last updated 2012-11-19

No results posted yet for this study

Summary

The observation period for each patient covered an initial treatment period with Avelox® plus optional 2 long-term follow-up periods (6 and 12 months).For each patient, the physician documented data at any initial visit (baseline) and at least one short-term follow-up visit (=initial treatment period).Optionally, long-term follow-ups (6 and 12 months) were documented, and a patient questionnaire was filled in.

Conditions

  • Bronchitis, Chronic
  • Bronchial Diseases

Interventions

DRUG

Moxifloxacin (Avelox, BAY12-8039)

AECB patients under daily life treatment receiving moxifloxacin according to the local product information.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • Austria
  • Brazil
  • China
  • Colombia
  • Croatia
  • Egypt
  • El Salvador
  • Germany
  • Hong Kong
  • Hungary
  • Indonesia
  • Malaysia
  • Mexico
  • Morocco
  • Netherlands
  • Pakistan
  • Philippines
  • Poland
  • Singapore
  • Slovenia
  • South Korea
  • Switzerland
  • Taiwan
  • Turkey (Türkiye)

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00932802 on ClinicalTrials.gov